• Consensus Rating: Moderate Buy
  • Consensus Price Target: $118.91
  • Forecasted Upside: 17.14%
  • Number of Analysts: 12
  • Breakdown:
  • 0 Sell Ratings
  • 6 Hold Ratings
  • 6 Buy Ratings
  • 0 Strong Buy Ratings
$101.51
▼ -0.58 (-0.57%)

This chart shows the closing price for RVTY by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Revvity Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for RVTY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for RVTY

Analyst Price Target is $118.91
▲ +17.14% Upside Potential
This price target is based on 12 analysts offering 12 month price targets for Revvity in the last 3 months. The average price target is $118.91, with a high forecast of $147.00 and a low forecast of $95.00. The average price target represents a 17.14% upside from the last price of $101.51.

This chart shows the closing price for RVTY for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 12 investment analysts is to moderate buy stock in Revvity. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 6 buy ratings
  • 6 hold ratings
  • 0 sell ratings
11/3/2022
  • 0 strong buy ratings
  • 6 buy ratings
  • 6 hold ratings
  • 0 sell ratings
2/1/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 6 hold ratings
  • 0 sell ratings
5/2/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 6 hold ratings
  • 0 sell ratings
7/31/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 6 hold ratings
  • 0 sell ratings
10/29/2023
  • 0 strong buy ratings
  • 6 buy ratings
  • 6 hold ratings
  • 0 sell ratings
1/27/2024
  • 0 strong buy ratings
  • 6 buy ratings
  • 6 hold ratings
  • 0 sell ratings
3/27/2024
  • 0 strong buy ratings
  • 6 buy ratings
  • 6 hold ratings
  • 0 sell ratings
4/26/2024

Latest Recommendations

  • 0 strong buy ratings
  • 6 buy ratings
  • 6 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/2/2024Stifel NicolausBoost TargetHold ➝ Hold$95.00 ➝ $110.00Low
2/2/2024Raymond JamesBoost TargetOutperform ➝ Outperform$106.00 ➝ $127.00Low
2/2/2024KeyCorpBoost TargetOverweight ➝ Overweight$110.00 ➝ $126.00Low
1/25/2024BarclaysBoost TargetEqual Weight ➝ Equal Weight$92.00 ➝ $105.00Low
1/16/2024UBS GroupDowngradeBuy ➝ Neutral$105.00 ➝ $125.00Low
1/4/2024Evercore ISIUpgradeIn-Line ➝ Outperform$88.00 ➝ $125.00Low
12/19/2023Wells Fargo & CompanyInitiated CoverageEqual Weight$95.00Low
12/13/2023Wolfe ResearchInitiated CoveragePeer PerformLow
10/31/2023Raymond JamesLower TargetOutperform ➝ Outperform$135.00 ➝ $106.00Low
10/31/2023The Goldman Sachs GroupLower TargetBuy ➝ Buy$120.00 ➝ $105.00Low
10/31/2023KeyCorpLower TargetOverweight ➝ Overweight$170.00 ➝ $110.00Low
10/18/2023Raymond JamesLower TargetOutperform ➝ Outperform$145.00 ➝ $135.00Low
10/17/2023JPMorgan Chase & Co.Lower TargetNeutral ➝ Neutral$130.00 ➝ $110.00Low
9/29/2023BarclaysLower TargetEqual Weight ➝ Equal Weight$130.00 ➝ $120.00Low
9/28/2023Sanford C. BernsteinInitiated CoverageOutperform$133.00Low
8/2/2023JPMorgan Chase & Co.Boost TargetNeutral ➝ Neutral$120.00 ➝ $130.00N/A
8/2/2023Robert W. BairdLower TargetOutperform ➝ Outperform$165.00 ➝ $147.00Low
8/2/2023BarclaysBoost TargetEqual Weight ➝ Equal Weight$125.00 ➝ $130.00Low
7/18/2023Raymond JamesInitiated CoverageOutperform$145.00Low
5/23/2023The Goldman Sachs GroupInitiated CoverageBuy ➝ BuyLow
(Data available from 4/26/2019 forward)

News Sentiment Rating

1.13 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/29/2023
  • 1 very positive mentions
  • 8 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
10/29/2023
  • 1 very positive mentions
  • 11 positive mentions
  • 8 negative mentions
  • 2 very negative mentions
11/28/2023
  • 2 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/28/2023
  • 3 very positive mentions
  • 14 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/27/2024
  • 6 very positive mentions
  • 17 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
2/26/2024
  • 8 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/27/2024
  • 21 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
4/26/2024

Current Sentiment

  • 21 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Revvity logo
Revvity, Inc. provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, BACS-on-Beads, BIOCHIPs, Bioo Scientific,BoBs , chemagic, Chitas, DELFIA, DELFIA Xpress, DOPlify, EONIS, EUROArray, EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, explorer, Fontus, Genoglyphix, GSP, Haoyuan, IDS, IDS-i10 IDS-i10T, IDS-iSYS, iLab, iQ, JANUS, LabChip, LifeCycle, LimsLink, Migele, MultiPROBE, NEXTFLEX, NextPrep, Pannoramic, Panthera Puncher, PG-Seq, PGFind PKamp, PreNAT II, Prime, Protein Clear, ProteinEXact, QSigh, QuantiVac, RONIA, Sciclone, SimplicityChrom, Specimen Gate,Superflex, Symbio, T-SPOT, Touch, Twister, Vanadis, VariSpec, ViaCord VICTOR 2D, and Zephyr brand name. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
Read More

Today's Range

Now: $101.51
Low: $101.01
High: $103.15

50 Day Range

MA: $104.68
Low: $99.33
High: $110.72

52 Week Range

Now: $101.51
Low: $79.50
High: $132.54

Volume

826,561 shs

Average Volume

848,738 shs

Market Capitalization

$12.54 billion

P/E Ratio

18.46

Dividend Yield

0.27%

Beta

1.09

Frequently Asked Questions

What sell-side analysts currently cover shares of Revvity?

The following equities research analysts have issued reports on Revvity in the last year: Barclays PLC, Evercore ISI, JPMorgan Chase & Co., KeyCorp, Raymond James, Robert W. Baird, Sanford C. Bernstein, Stifel Nicolaus, The Goldman Sachs Group, Inc., UBS Group AG, Wells Fargo & Company, and Wolfe Research.
View the latest analyst ratings for RVTY.

What is the current price target for Revvity?

11 Wall Street analysts have set twelve-month price targets for Revvity in the last year. Their average twelve-month price target is $118.91, suggesting a possible upside of 17.1%. Robert W. Baird has the highest price target set, predicting RVTY will reach $147.00 in the next twelve months. Wells Fargo & Company has the lowest price target set, forecasting a price of $95.00 for Revvity in the next year.
View the latest price targets for RVTY.

What is the current consensus analyst rating for Revvity?

Revvity currently has 6 hold ratings and 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for RVTY.

What other companies compete with Revvity?

How do I contact Revvity's investor relations team?

Revvity's physical mailing address is 940 WINTER STREET, WALTHAM MA, 02451. The company's listed phone number is (781) 663-6900 and its investor relations email address is [email protected]. The official website for Revvity is www.perkinelmer.com. Learn More about contacing Revvity investor relations.